Werewolf Therapeutics Stock Performance
| HOWL Stock | USD 0.64 0.02 2.77% |
The firm maintains a market beta of 1.91, which attests to a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Werewolf Therapeutics will likely underperform. At this point, Werewolf Therapeutics has a negative expected return of -0.72%. Please make sure to check out Werewolf Therapeutics' jensen alpha, kurtosis, as well as the relationship between the Kurtosis and period momentum indicator , to decide if Werewolf Therapeutics performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days Werewolf Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. Despite weak performance in the last few months, the Stock's basic indicators remain quite persistent which may send shares a bit higher in March 2026. The latest mess may also be a sign of long-standing up-swing for the company institutional investors. ...more
1 | Disposition of 48570 shares by Gadicke Ansbert of Werewolf Therapeutics at 1.18 subject to Rule 16b-3 | 11/10/2025 |
2 | Disposition of 55810 shares by Gadicke Ansbert of Werewolf Therapeutics at 1.14 subject to Rule 16b-3 | 11/11/2025 |
3 | Disposition of 57061 shares by Gadicke Ansbert of Werewolf Therapeutics at 0.95 subject to Rule 16b-3 | 11/17/2025 |
4 | Ansbert Gadicke Sells 61,640 Shares of Werewolf Therapeutics Stock | 11/19/2025 |
5 | Disposition of 88802 shares by Gadicke Ansbert of Werewolf Therapeutics at 0.98 subject to Rule 16b-3 | 11/24/2025 |
6 | Disposition of 20277 shares by Gadicke Ansbert of Werewolf Therapeutics at 0.99 subject to Rule 16b-3 | 11/28/2025 |
7 | Disposition of 60917 shares by Gadicke Ansbert of Werewolf Therapeutics at 0.94 subject to Rule 16b-3 | 12/01/2025 |
8 | Werewolf Therapeutics Director Luke Evnin Sells 38,978 Shares | 12/02/2025 |
9 | Disposition of 34041 shares by Evnin Luke of Werewolf Therapeutics at 0.99 subject to Rule 16b-3 | 12/08/2025 |
10 | Disposition of 44570 shares by Evnin Luke of Werewolf Therapeutics at 1.01 subject to Rule 16b-3 | 12/09/2025 |
11 | Disposition of 37104 shares by Evnin Luke of Werewolf Therapeutics at 1.06 subject to Rule 16b-3 | 12/10/2025 |
12 | Disposition of 28009 shares by Evnin Luke of Werewolf Therapeutics at 1.07 subject to Rule 16b-3 | 12/11/2025 |
13 | Disposition of 14548 shares by Evnin Luke of Werewolf Therapeutics at 1.05 subject to Rule 16b-3 | 12/16/2025 |
14 | Disposition of 9983 shares by Evnin Luke of Werewolf Therapeutics at 1.14 subject to Rule 16b-3 | 12/17/2025 |
15 | Disposition of 59307 shares by Evnin Luke of Werewolf Therapeutics at 0.69 subject to Rule 16b-3 | 12/22/2025 |
16 | Disposition of 71428 shares by Evnin Luke of Werewolf Therapeutics at 0.63 subject to Rule 16b-3 | 12/23/2025 |
17 | Disposition of 16310 shares by Evnin Luke of Werewolf Therapeutics at 0.65 subject to Rule 16b-3 | 12/24/2025 |
18 | Disposition of 35632 shares by Evnin Luke of Werewolf Therapeutics at 0.63 subject to Rule 16b-3 | 12/26/2025 |
19 | Werewolf Therapeutics, Inc. Short Interest Up 42.4 percent in December | 12/29/2025 |
20 | Disposition of 34847 shares by Evnin Luke of Werewolf Therapeutics at 0.61 subject to Rule 16b-3 | 12/30/2025 |
21 | Disposition of 24962 shares by Evnin Luke of Werewolf Therapeutics at 0.62 subject to Rule 16b-3 | 12/31/2025 |
22 | Disposition of 18568 shares by Evnin Luke of Werewolf Therapeutics at 0.63 subject to Rule 16b-3 | 01/02/2026 |
23 | Disposition of 18378 shares by Evnin Luke of Werewolf Therapeutics at 0.64 subject to Rule 16b-3 | 01/05/2026 |
24 | Disposition of 40761 shares by Evnin Luke of Werewolf Therapeutics at 0.65 subject to Rule 16b-3 | 01/06/2026 |
25 | Disposition of 11915 shares by Evnin Luke of Werewolf Therapeutics at 0.64 subject to Rule 16b-3 | 01/07/2026 |
26 | Disposition of 24678 shares by Evnin Luke of Werewolf Therapeutics at 0.61 subject to Rule 16b-3 | 01/09/2026 |
27 | Disposition of 43198 shares by Evnin Luke of Werewolf Therapeutics at 0.55 subject to Rule 16b-3 | 01/13/2026 |
28 | Disposition of 30616 shares by Evnin Luke of Werewolf Therapeutics at 0.57 subject to Rule 16b-3 | 01/14/2026 |
29 | Disposition of 37413 shares by Evnin Luke of Werewolf Therapeutics at 0.55 subject to Rule 16b-3 | 01/15/2026 |
30 | Disposition of 38782 shares by Evnin Luke of Werewolf Therapeutics at 0.54 subject to Rule 16b-3 | 01/16/2026 |
31 | Insider Selling Werewolf Therapeutics Director Sells 20,942.28 in Stock | 01/23/2026 |
| Begin Period Cash Flow | 155.6 M | |
| Total Cashflows From Investing Activities | -254 K |
Werewolf Therapeutics Relative Risk vs. Return Landscape
If you would invest 120.00 in Werewolf Therapeutics on November 6, 2025 and sell it today you would lose (55.91) from holding Werewolf Therapeutics or give up 46.59% of portfolio value over 90 days. Werewolf Therapeutics is currently does not generate positive expected returns and assumes 7.3216% risk (volatility on return distribution) over the 90 days horizon. In different words, 65% of stocks are less volatile than Werewolf, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Werewolf Therapeutics Target Price Odds to finish over Current Price
The tendency of Werewolf Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 0.64 | 90 days | 0.64 | about 81.06 |
Based on a normal probability distribution, the odds of Werewolf Therapeutics to move above the current price in 90 days from now is about 81.06 (This Werewolf Therapeutics probability density function shows the probability of Werewolf Stock to fall within a particular range of prices over 90 days) .
Werewolf Therapeutics Price Density |
| Price |
Predictive Modules for Werewolf Therapeutics
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Werewolf Therapeutics. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Werewolf Therapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Werewolf Therapeutics Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Werewolf Therapeutics is not an exception. The market had few large corrections towards the Werewolf Therapeutics' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Werewolf Therapeutics, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Werewolf Therapeutics within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | -1.09 | |
β | Beta against Dow Jones | 1.91 | |
σ | Overall volatility | 0.25 | |
Ir | Information ratio | -0.15 |
Werewolf Therapeutics Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Werewolf Therapeutics for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Werewolf Therapeutics can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Werewolf Therapeutics generated a negative expected return over the last 90 days | |
| Werewolf Therapeutics has high historical volatility and very poor performance | |
| Werewolf Therapeutics has some characteristics of a very speculative penny stock | |
| Werewolf Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 1.89 M. Net Loss for the year was (70.52 M) with loss before overhead, payroll, taxes, and interest of (50.48 M). | |
| Werewolf Therapeutics currently holds about 145.71 M in cash with (56.19 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.93, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Werewolf Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Latest headline from thelincolnianonline.com: Insider Selling Werewolf Therapeutics Director Sells 20,942.28 in Stock |
Werewolf Therapeutics Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Werewolf Stock often depends not only on the future outlook of the current and potential Werewolf Therapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Werewolf Therapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 43.9 M | |
| Cash And Short Term Investments | 111 M |
Werewolf Therapeutics Fundamentals Growth
Werewolf Stock prices reflect investors' perceptions of the future prospects and financial health of Werewolf Therapeutics, and Werewolf Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Werewolf Stock performance.
| Return On Equity | -1.22 | ||||
| Return On Asset | -0.41 | ||||
| Current Valuation | 6.76 M | ||||
| Shares Outstanding | 48.54 M | ||||
| Price To Earning | 0.84 X | ||||
| Price To Book | 1.08 X | ||||
| Price To Sales | 52.22 X | ||||
| Revenue | 1.89 M | ||||
| Gross Profit | (50.48 M) | ||||
| EBITDA | (64.05 M) | ||||
| Net Income | (70.52 M) | ||||
| Cash And Equivalents | 145.71 M | ||||
| Cash Per Share | 4.93 X | ||||
| Total Debt | 37.09 M | ||||
| Debt To Equity | 0.12 % | ||||
| Current Ratio | 5.08 X | ||||
| Book Value Per Share | 0.63 X | ||||
| Cash Flow From Operations | (56.19 M) | ||||
| Earnings Per Share | (1.62) X | ||||
| Market Capitalization | 32.93 M | ||||
| Total Asset | 126.93 M | ||||
| Retained Earnings | (414.59 M) | ||||
| Working Capital | 97.89 M | ||||
About Werewolf Therapeutics Performance
By examining Werewolf Therapeutics' fundamental ratios, stakeholders can obtain critical insights into Werewolf Therapeutics' financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Werewolf Therapeutics is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.64) | (0.67) | |
| Return On Capital Employed | (0.76) | (0.80) | |
| Return On Assets | (0.64) | (0.67) | |
| Return On Equity | (0.86) | (0.91) |
Things to note about Werewolf Therapeutics performance evaluation
Checking the ongoing alerts about Werewolf Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Werewolf Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Werewolf Therapeutics generated a negative expected return over the last 90 days | |
| Werewolf Therapeutics has high historical volatility and very poor performance | |
| Werewolf Therapeutics has some characteristics of a very speculative penny stock | |
| Werewolf Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 1.89 M. Net Loss for the year was (70.52 M) with loss before overhead, payroll, taxes, and interest of (50.48 M). | |
| Werewolf Therapeutics currently holds about 145.71 M in cash with (56.19 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.93, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Werewolf Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Latest headline from thelincolnianonline.com: Insider Selling Werewolf Therapeutics Director Sells 20,942.28 in Stock |
- Analyzing Werewolf Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Werewolf Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Werewolf Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Werewolf Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Werewolf Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Werewolf Therapeutics' stock. These opinions can provide insight into Werewolf Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Werewolf Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in child. For more information on how to buy Werewolf Stock please use our How to buy in Werewolf Stock guide.You can also try the Price Ceiling Movement module to calculate and plot Price Ceiling Movement for different equity instruments.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Werewolf Therapeutics. Market participants price Werewolf higher when confident in its future expansion prospects. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Werewolf Therapeutics assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Investors evaluate Werewolf Therapeutics using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Werewolf Therapeutics' intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. External factors like market trends, sector rotation, and investor psychology can cause Werewolf Therapeutics' market price to deviate significantly from intrinsic value.
Please note, there is a significant difference between Werewolf Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Werewolf Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Conversely, Werewolf Therapeutics' market price signifies the transaction level at which participants voluntarily complete trades.